Vinod Vathipadiekal

Vinod Vathipadiekal serves as the Vice President and Head of RNA Medicines at Alloy Therapeutics, Inc. since October 2022, while also holding positions as Board Director at Aldebaran Therapeutics and Founder of PiVA Biotechnology. Previously, Vathipadiekal was the Vice President and Head of Nucleic Acid Therapeutics at Leal Therapeutics, with a focus on project selection and team building, leading to significant contributions in patent submissions and laboratory capabilities. Experience at Eisai US involved leadership in ASO therapeutics and participation in global task forces, while earlier roles at Wave Life Sciences and Boston University School of Medicine emphasized advancements in RNAi technology and genomics in health-related studies. Educational credentials include a post-doctorate from Harvard University and a Ph.D. from the University of Pune, complemented by earlier studies in medical biochemistry and biotechnology.